Biohit Oyj (HEL: BIOBV)

Market Cap	35.22M
Revenue (ttm)	13.98M
Net Income (ttm)	1.65M
Shares Out	15.18M
EPS (ttm)	0.11
PE Ratio	21.26
Forward PE	17.85
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,040
Open	2.420
Previous Close	2.420
Day's Range	2.310 - 2.420
52-Week Range	1.800 - 2.650
Beta	0.82
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Biohit Oyj

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company’s diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist clinicians and general practitioner; Biohit Active B12, a test for measuring the levels of active vitamin B12; BIOHIT Total 25OH Vitamin D, a test for ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 46
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: BIOBV

Financial Performance

In 2023, Biohit Oyj's revenue was 13.08 million, an increase of 19.40% compared to the previous year's 10.95 million. Earnings were 1.85 million, an increase of 207.99%.